MNKD - MannKind Corporation
2.05 0.00 (0.00%)
After hours: 5:58PM EDT
| Previous Close | 1.93 |
| Open | 1.93 |
| Bid | 2.00 x 3200 |
| Ask | 2.05 x 1400 |
| Day's Range | 1.90 - 2.19 |
| 52 Week Range | 0.98 - 4.45 |
| Volume | 7,815,141 |
| Avg. Volume | 4,910,918 |
| Market Cap | 313.625M |
| Beta (3Y Monthly) | 3.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.99 |
| Earnings Date | Aug 6, 2018 - Aug 10, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.00 |
- ACCESSWIRE•2 days ago
Today’s Research Reports on Stocks to Watch: Altimmune and MannKind
NEW YORK, NY / ACCESSWIRE / October 17, 2018 / Altimmune and MannKind were two biotech stocks flying higher in Tuesday’s session. Altimmune didn’t have any particular news but MannKind announced along ...
- Motley Fool•2 days ago
Why MannKind Corp. Soared 16.4% Tuesday
The company has completed its planned transaction with United Therapeutics.
- GlobeNewswire•3 days ago
United Therapeutics and MannKind Announce Closing of License and Collaboration Agreement
United Therapeutics Corporation (UTHR) and MannKind Corporation (MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.
- PR Newswire•3 days ago
United Therapeutics And MannKind Announce Closing Of License And Collaboration Agreement
RESEARCH TRIANGLE PARK, N.C. and WESTLAKE VILLAGE, Calif., Oct. 16, 2018 /PRNewswire/ -- United Therapeutics Corporation (UTHR) and MannKind Corporation (MNKD) today announced the closing of their pending worldwide exclusive license and collaboration agreement for the development and commercialization of Treprostinil Technosphere®, a dry powder formulation of treprostinil being developed for the treatment of pulmonary arterial hypertension. MannKind Corporation (MNKD) focuses on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. MannKind is currently commercializing Afrezza® (insulin human) Inhalation Powder, the Company's first FDA-approved product and the only inhaled rapid-acting mealtime insulin in the United States, where it is available by prescription from pharmacies nationwide.
- GlobeNewswire•4 days ago
Afrezza® Inhaled Insulin Television Advertising Campaign Wins Gold Award for Creativity
MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, was recently awarded top honors for its first Afrezza® TV commercial, “Unexpected Moments,” at the Medical Marketing & Media (MM&M) awards ceremony last week. The company worked with precisioneffect, a Boston-based healthcare advertising agency, to produce the advertisement. “Managing mealtime control is crucial in order to help individuals living with diabetes optimize their outcomes,” said Michael Castagna, CEO of MannKind Corporation.
- Motley Fool•7 days ago
Here's What Sent MannKind Corporation Soaring 66.4% in September
A new collaboration agreement breathed life into the troubled manufacturer of inhaled insulin powder.
- GlobeNewswire•15 days ago
MannKind Presents Positive Afrezza® STAT Study Clinical Data at 54th Annual Meeting of the European Association for the Study of Diabetes
MannKind Corporation (MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension, presented data from the STAT study (STudy comparing prandial insulin Aspart vs. Technosphere insulin in patients with type 1 diabetes on multiple daily injections) at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany. The STAT study is the first randomized, controlled study to assess diabetes control using continuous glucose monitoring (CGM) and Afrezza® in individuals with type 1 diabetes.
- GlobeNewswire•16 days ago
MannKind Presents New Scientific Data at 54th Annual Meeting of the European Association for the Study of Diabetes
MannKind Corporation (MNKD), announced that it presented new scientific data in an oral and poster presentation at the 54th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Berlin, Germany. PS 097) both took place Tuesday, October 2, 2018.
- Motley Fool•21 days ago
MannKind Stock History
Here's the full story of how this biopharma got to where it is today.
- GlobeNewswire•25 days ago
MannKind Announces Completion of Cohort 1 and Opens Enrollment for Cohort 2 of Afrezza® Safety and Pharmacokinetics Study in Pediatric Patients
MannKind Corporation (MNKD) announced today that Cohort 2 of the Afrezza® safety and pharmacokinetics study in pediatric patients is now open for enrollment. The first group of individuals participating in the ongoing pediatric study of Afrezza, which included adolescents with type 1 diabetes aged 13-17 years old, was recently completed. The study findings to date support that the single‑dose pharmacokinetic (PK) profile of insulin levels for this age group is consistent with patterns seen in adult patients. In addition, dosing over a one‑month period demonstrated a safety profile consistent with that observed in adults.
- Thomson Reuters StreetEvents•last month
Edited Transcript of MNKD earnings conference call or presentation 2-Aug-18 9:00pm GMT
Q2 2018 MannKind Corp Earnings Call
- GlobeNewswire•last month
Positive Afrezza® Clinical Data from STAT Study Published in Diabetes Technology & Therapeutics
WESTLAKE VILLAGE, Calif., Sept. 13, 2018-- MannKind Corporation announced today that "Improved Postprandial Glucose with Inhaled Technosphere ® Insulin Compared to Insulin Aspart in Patients with ...
- Zacks•last month
Implied Volatility Surging for MannKind (MNKD) Stock Options
MannKind (MNKD) needs investors to pay close attention to the stock based on moves in the options market lately.
- ACCESSWIRE•last month
Mannkind Afrezza Sales Have Doubled and Treprostinil is Getting Some Traction
NEW YORK, NY / ACCESSWIRE / September 10, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on MannKind Corporation (NASDAQ: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. On September 4th, MannKind announced that they have entered into a worldwide exclusive licensing and collaboration agreement for the development and commercialization of a dry powder formulation of treprostinil, an investigational product currently being evaluated in clinical trials for the treatment of pulmonary arterial hypertension. MNKD doubled its market share over the past year as a result of its commercialization efforts and are excited about its new Afrezza clinical data being released throughout 2018.
- Motley Fool•last month
Is MannKind Corporation Stock a Buy?
A new collaboration is funneling tens of millions of dollars onto the diabetes company’s balance sheet.
- Motley Fool•last month
3 Biotech Stocks That Soared This Week: Are They Buys?
Big news lit a fire under these biotech stocks this week. But can their momentum continue?
- Motley Fool•last month
A New Deal Moves MannKind Back From the Brink
A new cash lifeline from United Therapeutics buys the diabetes drugmaker more time to increase sales of its inhaled insulin. Also, make-or-break news is fast approaching for cardiovascular drugmaker Amarin.
- Zacks•last month
The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals
The Zacks Analyst Blog Highlights: Amgen, Puma Biotechnology, MannKind, United Therapeutics and Vertex Pharmaceuticals
- InvestorPlace•last month
New Development Partnership Could Pay Off Big for MannKind Stock
After spending much of 2017 in a downtrend, MannKind (NASDAQ:MNKD) lit up on the stock market and closed above $2.00 a share on Sept. 4 for the first time since June. The company announced that it would collaborate with United Therapeutics (NASDAQ:UTHR) on treprostinil, an investigational drug for the treatment of pulmonary arterial hypertension. The cash infusion from the deal is just what MannKind needed.
- Motley Fool•last month
Why Cronos Group, MannKind, and Vera Bradley Jumped Today
Find out the latest buzz on these winners.
- Zacks•last month
MannKind Stock Up on Licensing Deal With United Therapeutics
MannKind (MNKD) out-licenses rights to its investigational dry powder formulation of treprostinil to United Therapeutics for treating pulmonary arterial hypertension.
- Motley Fool•last month
The Probable Reason Why MannKind Corporation Is Rallying Again
Shares soar for the second day in a row. What can explain the bullish move?
- Zacks•last month
Biotech Stock Roundup: AMGN, PBYI Get EC Nod for Their Drugs, MNKD Soars
Drug approvals in Europe and other pipeline updates comprise some of the key developments in the biotech sector this week.
- Market Realist•last month
United Therapeutics Enters into a Collaboration with MannKind
United Therapeutics and MannKind’s collaboration is for an investigational treprostinil dry powder that is presently in clinical trials. According to the terms of the agreement, United Therapeutics (UTHR) is responsible for the development, regulatory activities, and commercialization of this dry powder.
- InvestorPlace•last month
Why MannKind Stock Is Skyrocketing Today
The good news for MNKD stock comes in the form of an agreement to have it manufacture a dry powder formulation of treprostinil. This is a drug that is currently in testing for treating pulmonary arterial hypertension. The deal will have MannKind acting as the manufacturer for clinical supplies of the drug and its initial commercial run. For its efforts, the company is getting an upfront payment of $45 million.
